Xoft Inc.: Electronic Brachytherapy Offers Safe, Convenient Alternative to Traditional Therapy Across Broad Range of Cancers
Published: Aug 03, 2010
"Building on several recent publications validating IORT using Electronic Brachytherapy, the 14 AAPM presentations further expand the body of research supporting the safety and efficacy of the Axxent System across a wide range of cancers," said Michael Klein, president and CEO of Xoft. "The AAPM presentations demonstrate that the isotope-free cancer treatment platform is safe, convenient alternative to deliver IORT for breast and other cancers that is professionally validated and patient friendly."
Several studies continue to demonstrate the ability of Electronic Brachytherapy to deliver equivalent treatment results to traditional isotopic therapies with reduced exposure to surrounding healthy tissues and other studies validate its safety and performance. Another series of studies explored extending the utilization of Electronic Brachytherapy with new applications to the treatment of breast and other cancers, including skin and endocavitary cancer.
Researchers from Washington University in St Louis evaluated the ability of Electronic Brachytherapy to serve as an alternative for the treatment of early stage rectal carcinoma in the study, "A New Technique for Endocavitary Radiotherapy: Treatment with an Electronic Brachytherapy Source." Results of the dosimetric comparison between the historically used Philips RT-50 (papillon technique) and the Xoft Axxent System were presented. Based on equivalent treatment dose and reduced exposure to treatment professionals, results demonstrated that Electronic Brachytherapy may be an excellent dosimetric replacement to the Philips RT-50 Endocavitary Unit for treatment of endocavitary cancers. With the benefits associated with the non-isotopic, electronic source, researchers concluded that this new technology may increase utilization of endocavitary radiotherapy.
The study "Comparison of Tumor and Normal Tissue Dose for Accelerated Partial Breast Irradiation Using an Electronic Brachytherapy eBx Source and Iridium-192 Source," compared treatment plans for patients treated with Electronic Brachytherapy (eBx) using the Axxent® System as adjuvant therapy for early stage breast cancer with treatment plans prepared from the same CT image sets using an Iridium-192 (Ir-192) source. Results demonstrated that both forms of balloon-based brachytherapy provide comparable dose to the planning target volume (PTV). However, Electronic Brachytherapy is associated with a considerably increased dose within the PTV near the surface of the balloon and decreased dose outside the PTV, resulting in significantly reduced dose to the heart, ipsilateral lung and healthy organs and tissue. These results are comparable to data published in Brachytherapy: Dickler, et al. "A dosimetric comparison of MammoSite high dose rate brachytherapy and Xoft Axxent electronic brachytherapy," Brachytherapy (6) 2007, 164-168.
About Axxent Electronic Brachytherapy
Available for treatment of early stage breast cancer, endometrial cancer, and skin cancer, the Axxent eBx System is also FDA cleared for use in the treatment of surface cancers or conditions where radiation therapy is indicated, including IORT (intraoperative radiation therapy). As a platform technology, the Axxent System is designed to deliver non-radioactive therapy directly to cancerous tissue with minimal radiation exposure to surrounding healthy tissue. Utilizing a proprietary miniaturized X-ray source and robotic controller, treatment can be performed in minimally shielded therapeutic settings allowing the radiation oncologist and other medical personnel to be present during treatment delivery and minimizing patient anxiety.
About Xoft, Inc.
Xoft develops Electronic Brachytherapy (eBx) systems based upon miniaturized X-ray tube technology for the practice of radiation oncology in virtually any clinical setting, eliminating the need for heavily shielded environments. The Axxent® treatment platform provides a therapeutic dose of radiation directly to the region at risk with minimal radiation exposure to surrounding healthy tissue and without the logistics and costs associated with using radioactive isotopes. Available for treatment of early stage breast cancer, skin cancer and endometrial cancer, the Axxent System is also cleared for use in the treatment of other cancers or conditions where radiation therapy is indicated. For information, visit www.xoftinc.com.
Axxent is a registered trademark and eBx is a trademark of Xoft, Inc.
SOURCE Xoft, Inc.